AR030275A1 - Composicion que inhibe la apoptosis y uso de un compuesto 15-ceto-prostaglandina- para producirla - Google Patents

Composicion que inhibe la apoptosis y uso de un compuesto 15-ceto-prostaglandina- para producirla

Info

Publication number
AR030275A1
AR030275A1 ARP010101368A ARP010101368A AR030275A1 AR 030275 A1 AR030275 A1 AR 030275A1 AR P010101368 A ARP010101368 A AR P010101368A AR P010101368 A ARP010101368 A AR P010101368A AR 030275 A1 AR030275 A1 AR 030275A1
Authority
AR
Argentina
Prior art keywords
group
heterocyclic
oxo
aryl
hydroxyl
Prior art date
Application number
ARP010101368A
Other languages
English (en)
Spanish (es)
Original Assignee
Sucampo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Pharmaceuticals Inc filed Critical Sucampo Pharmaceuticals Inc
Publication of AR030275A1 publication Critical patent/AR030275A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP010101368A 2000-03-24 2001-03-23 Composicion que inhibe la apoptosis y uso de un compuesto 15-ceto-prostaglandina- para producirla AR030275A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19175500P 2000-03-24 2000-03-24

Publications (1)

Publication Number Publication Date
AR030275A1 true AR030275A1 (es) 2003-08-20

Family

ID=22706808

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101368A AR030275A1 (es) 2000-03-24 2001-03-23 Composicion que inhibe la apoptosis y uso de un compuesto 15-ceto-prostaglandina- para producirla

Country Status (13)

Country Link
US (1) US7129272B2 (https=)
EP (1) EP1267882B1 (https=)
JP (1) JP2003527430A (https=)
KR (1) KR100788226B1 (https=)
CN (1) CN1443070A (https=)
AR (1) AR030275A1 (https=)
AT (1) ATE428429T1 (https=)
AU (2) AU3955101A (https=)
CA (1) CA2403086C (https=)
DE (1) DE60138371D1 (https=)
NZ (1) NZ521464A (https=)
TW (1) TWI284535B (https=)
WO (1) WO2001070233A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1420794B1 (en) 2001-08-31 2017-12-27 Sucampo AG Prostaglandin analogs as chloride channel openers
CN1605336A (zh) 2003-10-10 2005-04-13 中国医学科学院药物研究所 左旋丁基苯酞在制备预防和治疗脑梗塞的药物中的应用
DK1841433T3 (da) * 2005-01-27 2012-01-16 Sucampo Ag Præparat til behandling af lidelser i centralnervesystemet
KR101396731B1 (ko) * 2005-03-31 2014-05-19 산텐 세이야꾸 가부시키가이샤 프로스타글란딘 F2a 유도체를 유효 성분으로서 함유하는망막신경세포 보호제
CN101160128B (zh) 2005-04-13 2010-08-18 宇部兴产株式会社 含有吲唑衍生物作为有效成分的视网膜神经细胞保护剂
US20070037193A1 (en) * 2005-08-12 2007-02-15 Rong-Hwa Lin Modulation of peroxisome proliferator-activated receptors
US8871752B2 (en) 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
WO2010027040A1 (ja) * 2008-09-04 2010-03-11 参天製薬株式会社 15,15-ジフルオロプロスタグランジンF2α誘導体を有効成分として含有する毛髪成長促進剤
US9084815B2 (en) * 2009-09-16 2015-07-21 Sucampo Ag Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
ES2052735T3 (es) * 1987-09-18 1994-07-16 R Tech Ueno Ltd Un metodo para producir un agente hipotensor ocular.
CA2030345C (en) * 1989-11-22 1998-12-08 Ryuji Ueno Use of 15-keto-prostaglandin compound for improvement of encephalic function
JPH0761944B2 (ja) * 1989-11-22 1995-07-05 株式会社アールテック・ウエノ 脳機能改善処置剤
TW224942B (https=) 1990-04-04 1994-06-11 Adka Ueno Kk
CA2150287C (en) 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
JP3625946B2 (ja) * 1995-03-10 2005-03-02 株式会社アールテック・ウエノ 視神経障害改善剤
JPH08277222A (ja) * 1995-04-05 1996-10-22 Green Cross Corp:The 神経疾患の予防治療剤
US6087395A (en) 1997-10-21 2000-07-11 Japan Science And Technology Corporation Isocarbacyclin derivatives as apoptosis inhibitors
JP3964060B2 (ja) * 1997-10-21 2007-08-22 独立行政法人科学技術振興機構 アポトーシス抑制剤
JP2000169394A (ja) * 1998-12-04 2000-06-20 Yoshitomi Pharmaceut Ind Ltd アポトーシス誘導剤

Also Published As

Publication number Publication date
WO2001070233A2 (en) 2001-09-27
TWI284535B (en) 2007-08-01
AU2001239551B8 (en) 2005-11-24
NZ521464A (en) 2004-09-24
JP2003527430A (ja) 2003-09-16
CA2403086C (en) 2010-08-17
ATE428429T1 (de) 2009-05-15
DE60138371D1 (de) 2009-05-28
CA2403086A1 (en) 2001-09-27
EP1267882B1 (en) 2009-04-15
WO2001070233A3 (en) 2002-06-13
KR20020081474A (ko) 2002-10-26
AU2001239551B2 (en) 2005-07-21
EP1267882A2 (en) 2003-01-02
US7129272B2 (en) 2006-10-31
CN1443070A (zh) 2003-09-17
US20020025985A1 (en) 2002-02-28
KR100788226B1 (ko) 2007-12-26
AU3955101A (en) 2001-10-03

Similar Documents

Publication Publication Date Title
AR100696A2 (es) Uso de un compuesto de 15-ceto-prostaglandina para fabricar una composición para tratar estreñimiento inducido por drogas
AR036391A1 (es) Uso de un compuesto de prostaglandina para preparar una composicion farmaceutica para abrir los canales de cic en un mamifero y compuestos de prostaglandina
AR030275A1 (es) Composicion que inhibe la apoptosis y uso de un compuesto 15-ceto-prostaglandina- para producirla
ES2104072T3 (es) Redistribucion de composiciones de policarbonato organico.
AR074465A2 (es) Uso de derivados de acidos grasos para tratamiento de desordenes de secrecion externa
PE20221341A1 (es) Derivados de piridazin-3(2h)-ona fusionados con azol
HN1998000155A (es) Medicamentos
ES2175350T3 (es) Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
CO5700742A2 (es) Moduladores del receptor de quimioquina ccr5
AR032465A1 (es) Derivados anticonvulsivos utiles para la preparacion de un medicamento para prevenir el desarrollo de la diabetes mellitus de tipo ii y del sindrome x
ES2149215T3 (es) Bencilaminoquinuclidinas sustituidas como antagonistas de la sustancia p.
ATE312087T1 (de) Zyklische äther vitamin d3 verbindungen, 1alfa(oh) 3-epi-vitamin d3 verbindungen und deren verwendungen
CO4700455A1 (es) Derivados tetraciclicos y proceso para su preparacion
AR056980A1 (es) Derivados de dihidrobenzofurano, composiciones farmaceuticas, y uso de los mismos
AR066962A1 (es) Compuesto heterociclico fusionado
AR110149A2 (es) Composición catártica
AR036044A1 (es) Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma
CO5590916A2 (es) Dicetopiperacinas sustituidas como antagonistas de oxitocina
ES2070238T3 (es) Emulsion de lipidos que contiene un analogo de prostaglandina.
AR030277A1 (es) Composicion promotora de la secrecion biliar y uso de 15-ceto-prostaglandina para producirla
DOP2005000035A (es) Nuevos derivados de bencil (ideno)- lactamas
AR055846A1 (es) Compuesto de prostaglandina y metodo para tratar trastornos del sistema nervioso central
DK578887D0 (da) Antihypertensiva
SV2002000503A (es) Nuevo procedimiento para la preparacion de pirazolopirimidinonas ref. pcs10383afae
AR041080A1 (es) Compuestos de 5- croman- 5- il- etilamina substituidos y su uso para el tratamiento de glaucoma

Legal Events

Date Code Title Description
FB Suspension of granting procedure